Status:
WITHDRAWN
Type 2 Innate Lymphoid Cells in Severe Pediatric Asthma
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
URC-CIC Paris Descartes Necker Cochin
Conditions:
Severe Asthma
Eligibility:
All Genders
6-18 years
Brief Summary
The main objectives of this study are to show that the number of type 2 innate lymphoid cells (ILC2) of the bronchial mucosa and in bronchoalveolar lavages (BAL) are higher in asthmatic children than ...
Detailed Description
Severe asthma of the child is characterized by chronic eosinophilic infiltration of the bronchial mucosa associated with bronchial remodeling. The mechanisms responsible for these phenomena are still...
Eligibility Criteria
Inclusion
- Controls :
- Minors aged 6 to 18 matched in age with severe asthmatic children
- Non-asthmatic children hospitalized in the department of pediatric pulmonology and allergy in Necker Hospital
- To undergo bronchial endoscopy with bronchoalveolar lavage, biopsy and blood collection
- Severe asthmatic children :
- Minors aged 6 to 18
- Children hospitalized in the department of pediatric pulmonology and allergy in Necker Hospital
- To undergo bronchial endoscopy with bronchoalveolar lavage, biopsy and blood collection
- Severe uncontrolled asthma is defined by the need to maintain a treatment with high doses of inhaled corticosteroids and a long-acting bronchodilator (B2LDA) and/or an anti-leukotriene
Exclusion
- Children with an immune deficiency, will be excluded
Key Trial Info
Start Date :
June 9 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03784781
Start Date
June 9 2016
End Date
April 1 2020
Last Update
September 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Necker Enfants malades
Paris, France, 75015